A novel vaccine approach for chagas disease using rare adenovirus serotype 48 vectors

2Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

© 2016 by the authors; licensee MDPI, Basel, Switzerland. Due to the increasing amount of people afflicted worldwide with Chagas disease and an increasing prevalence in the United States, there is a greater need to develop a safe and effective vaccine for this neglected disease. Adenovirus serotype 5 (Ad5) is the most common adenovirus vector used for gene therapy and vaccine approaches, but its efficacy is limited by preexisting vector immunity in humans resulting from natural infections. Therefore, we have employed rare serotype adenovirus 48 (Ad48) as an alternative choice for adenovirus/Chagas vaccine therapy. In this study, we modified Ad5 and Ad48 vectors to contain T. cruzi’s amastigote surface protein 2 (ASP-2) in the adenoviral early gene. We also modified Ad5 and Ad48 vectors to utilize the “Antigen Capsid-Incorporation” strategy by adding T. cruzi epitopes to protein IX (pIX). Mice that were immunized with the modified vectors were able to elicit T. cruzi-specific humoral and cellular responses. This study indicates that Ad48-modified vectors function comparable to or even premium to Ad5-modified vectors. This study provides novel data demonstrating that Ad48 can be used as a potential adenovirus vaccine vector against Chagas disease.

Cite

CITATION STYLE

APA

Farrow, A. L., Peng, B. J., Gu, L., Krendelchtchikov, A., & Matthews, Q. L. (2016). A novel vaccine approach for chagas disease using rare adenovirus serotype 48 vectors. Viruses, 8(3). https://doi.org/10.3390/v8030078

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free